Past Press Releases - REVOTAR Biopharmaceuticals

September 15, 2009
Revotar Biopharmaceuticals AG receives 2.5 million euro research grant
Revotar Biopharmaceuticals AG today announced that the company has been granted 2.5 million Euro from the German Federal State of Brandenburg for the development of its pipeline of selectin antagonists in respiratory indications. More

July 3, 2009
Revotar to initiate phase IIa study of Bimosiamose to support development in COPD
Revotar Biopharmaceuticals AG today announced the submission of a Phase IIa study to evaluate the effect of Bimosiamose on ozone-induced sputum neutrophilia in healthy subjects with a new controlled breathing nebulizer device. More

June 3, 2009
Revotar Biopharmaceuticals AG announces changes in management and board
Revotar Biopharmaceuticals AG announces the appointment of Ludwig Felber as chief financial officer and member of the executive board and the election of Prof Dr Wolfgang Hartwig as new supervisory board member. More

October 28, 2008
Revotar reports positive preclinical data from a 4-month dermal toxicity study
Revotar Biopharmaceuticals AG today announced preclinical data from a dermal toxicity study demonstrating that topical administration of Bimosiamose cream in minipigs was safe and well tolerated. More

October 13, 2008
Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream
Revotar Biopharmaceuticals AG today announced data from a Phase I study demonstrating that the topical application of its Bimosiamose 5% Cream in patients with plaque psoriasis has been safe and well tolerated. More

September 22, 2008
Revotar closes 5.3 million EUR Series A financing round
Revotar Biopharmaceuticals AG today announced the successful closing of its Series A financing round of 5.3 million EUR. More